" class="no-js "lang="en-US"> Motoo Nishihara - Medtech Alert
Tuesday, January 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Motoo Nishihara

Motoo Nishihara

About Motoo Nishihara

Related Story

Companies

 NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets | Pharmtech Focus

NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets

March 9 2022

NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech […]

Diseases

 Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050

Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine

November 23 2021

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment […]